Bladder cancer: what's new in 2021-2022

被引:0
作者
Karyakin, O. B. [1 ]
机构
[1] Minist Hlth Russia, Branch Natl Med Res Radiol Ctr, AF Tsyb Med Radiol Res Ctr, 4 Koroleva St, Obninsk 249031, Russia
来源
ONKOUROLOGIYA | 2022年 / 18卷 / 04期
关键词
bladder cancer; genetic marker; cystectomy; organ-saving treatment;
D O I
10.17650/1726-9776-2022-18-4-141-146
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This review presents the main lines of research on bladder cancer in 2021 and 2022. The review largely focuses on molecular studies in the context of primary diagnosis and disease progression. Based on molecular and genetic data, 3 main types of bladder cancer with varying sensitivity to chemotherapy drugs can be identified. The main treatment approach to invasive bladder cancer is cystectomy. Data on complications after radical cystectomy in different followup periods depending on experience, as well as comparative results of open and robot-assisted surgeries in the context of time expenditure and complications are discussed. Methods of organ-saving treatment as alternatives to cystectomy are being developed. New regimens of drug treatment in combination with external beam radiotherapy are being investigated. In some studies, results of drug treatment are equal to results of radical cystectomy. Active investigation of new chemotherapy drugs for improvement of treatment results of advanced bladder cancer continues.
引用
收藏
页码:141 / 146
页数:6
相关论文
共 16 条
[1]   Contemporary analysis of cystectomy complications. [J].
Chua, Kevin Joseph ;
Patel, Hiren V. ;
Srivastava, Arnav ;
Doppalapudi, Sai Krishnaraya ;
Lichtbroun, Benjamin ;
Elsamra, Sammy ;
Singer, Eric A. ;
Jang, Thomas L. ;
Ghodoussipour, Saum .
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[2]  
De Jong F.C., 2021, J UROLOGY, V207, DOI [10.1101/2021.11.30.21266988, DOI 10.1101/2021.11.30.21266988]
[3]  
De Ruiter B., 2022, 37 ANN EAU C
[4]   Molecular and Pharmacological Bladder Cancer Therapy Screening: Discovery of Clofarabine as a Highly Active Compound [J].
Ertl, Iris E. ;
Lemberger, Ursula ;
Ilijazi, Dafina ;
Hassler, Melanie R. ;
Bruchbacher, Andreas ;
Brettner, Robert ;
Kronabitter, Hannah ;
Gutmann, Michael ;
Vician, Petra ;
Zeitler, Gerhard ;
Koren, Anna ;
Lardeau, Charles-Hugues ;
Mohr, Thomas ;
Haitel, Andrea ;
Comperat, Eva ;
Oszwald, Andre ;
Wasinger, Gabriel ;
Clozel, Thomas ;
Elemento, Olivier ;
Kubicek, Stefan ;
Berger, Walter ;
Shariat, Shahrokh F. .
EUROPEAN UROLOGY, 2022, 82 (03) :261-270
[5]  
Farha M., 2022, 37 ANN EAU C
[6]  
Garg H., 2022, 37 ANN EAU C
[7]   Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trial [J].
Hall, Emma ;
Hussain, Syed A. ;
Porta, Nuria ;
Lewis, Rebecca ;
Crundwell, Malcolm ;
Jenkins, Peter ;
Rawlings, Christine ;
Tremlett, Jean ;
Sreenivasan, Thiagarajan ;
Wallace, Jan ;
Syndikus, Isabel ;
Sheehan, Denise ;
Lydon, Anna ;
Huddart, Robert ;
James, Nicholas .
EUROPEAN UROLOGY, 2022, 82 (03) :273-279
[8]   SUB-urothelial durvalumab injection: 1 (SUBDUE-1)-Results from the first nine urothelial cancer patients using a dose-escalation schedule. [J].
Hayne, Dickon ;
Swarbrick, Nicole ;
McCombie, Stephen ;
Moe, Andrew ;
Hawks, Cynthia ;
Viswambaram, Pravin ;
Conduit, Ciara ;
Liow, Elizabeth Chien Hern ;
Spalding, Lisa ;
Bothe, Jarrad ;
Ferguson, Tom ;
Martin, Andrew James ;
Davis, Ian D. ;
Redfern, Andrew David .
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[9]  
Khetrapal P., 2022, JAMA-J AM MED ASSOC, V207, DOI 10.1097/JU.0000000000002603.02
[10]   Gemcitabine and carboplatin versus gemcitabine and paclitaxel chemotherapy in cisplatin ineligible advanced-stage urothelial cancers: A prospective randomized control study. [J].
Kumar, Parmod ;
Sehrawat, Amit ;
Sundriyal, Deepak ;
Sharma, Pankaj ;
Mittal, Ankur ;
Gupta, Manoj Kumar .
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)